Vasculitis in Behçet's syndrome: Evidence-based review

Current Opinion in Rheumatology

Volumn 20, Issue 3, 2008, Pages 347-352

  Reynolds, Neil ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; BENZATHINE PENICILLIN; CHLORAMBUCIL; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; METHYLPREDNISOLONE; PREDNISOLONE; THALIDOMIDE;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ALOPECIA; ANOREXIA; AUTOIMMUNE DISEASE; BEHCET DISEASE; CENTRAL NERVOUS SYSTEM; CHILL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPEPSIA; ERYTHEMA NODOSUM; EVIDENCE BASED PRACTICE; FACE EDEMA; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GINGIVA HYPERTROPHY; HEMOGLOBIN BLOOD LEVEL; HIRSUTISM; HUMAN; HYPERTRICHOSIS; INCREASED APPETITE; KIDNEY DISEASE; LEUKOPENIA; MYALGIA; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; RETINA VASCULITIS; REVIEW; SIDE EFFECT; SKIN DISEASE; SKIN NODULE; THROMBOPHLEBITIS; THROMBOSIS; UVEITIS; VASCULITIS; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS; BEHCET SYNDROME; ERYTHEMA NODOSUM; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UVEITIS; VASCULITIS;

EID: 41649113731     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282ff0d51     Document Type: Review

References (34)

1. Kontogianis V, Powell RJ. Behçet's disease. Postgrad Med J 2000; 76:629-637.
2. Goker B, Goker H. Current therapy for Behçet's disease. Am J Ther 2002; 9:465-470.
3. Idil A, Gurler A, Boyvat A, et al. The prevalence of Behçet's disease above the age of 10 years: the results of a pilot study conducted at the Park Primary Health Care Center in Ankara, Turkey. Ophthalmic Epidemiol 2002; 9:325-331.
4. Yurdakul S, Gunaydin I, Turzun Y, et al. The prevalence of Behçet's syndrome in a rural area in Northern Turkey. J Rheumatol 1998; 15:820-822.
5. Chamberlein M. Behçet's syndrome in 32 patients in Yorkshire. Ann Rheum Dis 1977; 36:491-499.
6. Ohno S, Ohguchi M, Hirose S, et al. Close association of HLA Bw51 in Behçet's disease. Arch Ophthalmol 1982; 100:1455-1458.
7. Morelli S, Perrone C, Ferrante L, et al. Cardiac involvement in Behçet's disease. Cardiology 1997; 88:513-517.
8. Arber N, Klein T, Meiner Z, et al. Close association of HLA-B51 and B52 in Israeli patients with Behçet's syndrome. Ann Rheum Dis 1991; 50:351-353.
9. Bird Stewart J. Genetic analysis of families of patients with Behçet's syndrome: data incompatible with autosomal recessive inheritance. Ann Rheum Dis 1986; 45:265-268.
10. Karasneh J, Gul A, Ollier WE, et al. Whole-genome screening for susceptibility genes in multicase families with Behçet's disease. Arthritis Rheum 2005; 52:1836-1842.
11. Eglin R, Lehner T, Suback-Sharpe J. Detection of RNA complementary herpes-simplex virus in mononuclear cells from patients with Behçet's syndrome and recurrent oral ulceration. Lancet 1982; 2:1356-1360.
12. Studd M, McCance D, Lehner T. Detection of HSV-1 DNA in patients with Behçet's syndrome and in patients with recurrent oral ulcers by the polymerase chain reaction. J Med Microbiol 1991; 34:39-43.
13. Yoshikawa K, Kotake S, Matsuda H. Behçet's disease and streptococcal antigens. Nippon Ganka Gakkai Zasshi 1996; 100:173-180.
14. Mizushima Y, Matsuda T, Hoshi K, et al. Induction of Behçet's disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol 1988; 15:1029-1030.
15. Hazleman B. Rheumatic disorders of the eye and the various structures involved. Br J Rheumatol 1996; 35:258-268.
16. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet's disease: an analysis of 880 patients. Am J Ophthalmol 2004; 138:373-380.
17. Calamia KT, Schirmer M, Melikoglu M. Major vessel involvement in Behcet disease. Curr Opin Rheumatol 2005; 17:1-8.
18. Demirkesen C, Tuzuner N, Mat C, et al. Clinicopathologic evaluation of nodular cutaneous lesions of Behçet's syndrome. Am J Clin Pathol 2001; 116:341-346.
19. Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain 1999; 122:2171-2182.
20. Siva A, Kantarci OH, Saip S, et al. Behçet's disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 2001; 248:95-103.
21. Zouboulis CC, Orfanos CE. Treatment of Adamantiades-Behcet disease with systemic interferon alfa. Arch Dermatol 1998; 134:1010-1016.
22. Yazici H, Pazarli H, Barnes C, et al. A controlled trial of azathioprine in Behçet's syndrome. New Engl J Med 1990; 322:281-285.
23. Calguneri M, Ertenli I, Kiraz S, et al. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease. Dermatology 1996; 192:125-128.
24. BenEzra D, Cohen T, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behçet's syndrome. Transplant Proc 1988; 20:136-143.
25. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1989; 1:1093-1096.
26. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 2001; 44:2686-2692.
27. Aktulga E, Altac M, Muftuoglu A, et al. A double blind study of colchicine in Behçet's disease. Haematologica 1980; 65:399-402.
28. Davatchi F, Shahram F, Chams H, et al. Pulse cyclophosphamide in ocular manifestations of Behçet's disease: a double-blind controlled crossover study. Arch Iranian Med 2004; 7:201-205.
29. Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçet's disease: a double-blind, placebo-controlled, cross-over study. J Dermatol 2002; 29:267-279.
30. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002; 138:467-471.
31. Mat C, Yurdakul S, Uysal S, et al. A double-blind trial of depot corticosteroids in Behçet's syndrome. Rheumatology 2006; 45:348-352.
32. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet's syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:443-450.
33. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997; 40:769-774.
34. Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Behcet syndrome. Am J Med 2004; 117:867-870.